Substituted 1,3-dioxanes useful as PPAR modulators

Patent metadata

Field	Value
Publication number	US-9260406-B2
Application number	US-201313788768-A
Country	US
Kind code	B2
Filing date	Mar 7, 2013
Priority date	Jan 18, 2007
Publication date	Feb 16, 2016
Grant date	Feb 16, 2016

Abstract

Specifically useful stereoisomers of 1,3-dioxane derivatives are described and their use in the treatment of a disease or condition dependent on PPAR modulation, such as diabetes, cancer, inflammation, neurodegenerative disorders and infections as well as their use in the treatment of a disease related to TP, such as cardiovascular diseases.

First claim

The invention claimed is:

1. A compound of formula X

or a pharmaceutically acceptable salt thereof
wherein A is a branched or linear carbon chain of 3 to 7 carbons, optionally containing 1 or 2 double bonds; and
W is COOH, C(O)NH—OH, NH 2 , SO 3 H, OSO 3 H, an aromatic group (optionally substituted with COOH, OH or NH 2 ) or —C(O)-Rd,
wherein Rd is —NH—C 1-6 -alkyl (branched or linear), —O—C 1-6 -alkyl (branched or linear) or a saccharide; and
Ar is a phenyl, or a 5 or 6 membered heterocyclic aromatic group optionally substituted with O-Rc,
wherein Rc is C 1-6 -alkyl (branched or linear), —C(O)—C 1-6 -alkyl (branched or linear), —CH(O), a saccharide or —H; and
Rb is 2-6 C alkenyl, 1 -8 C alkyl optionally substituted with up to three halogeno substituents, saccharide, pentafluorophenyl, aryl or aryl( 1-4 C)alkyl, the latter two of which may optionally have up to five substituents selected from halogeno, ( 1-6 C)alkyl, branched or linear ( 1-6 C)alkoxy, ( 1-4 C)alkylenedioxy, trifluoromethyl, cyano, nitro, hydroxyl, ( 2-6 C)alkanoyloxy, ( 1-6 C)alkylthio, (1-6C)alkanesulphonyl, ( 1-6 C)alkanoylamino and oxapolymethylene of 2 to 4 carbon atoms,
wherein the compound or salt is crystalline.

2. A compound of formula XI:

or a pharmaceutically acceptable salt thereof
wherein X is selected from the group consisting of fluoro, chloro, bromo, trifluoromethyl, substituted phenyl, cyano, methoxy, nitro, hydroxyl and —H; and
Y is selected from the group consisting of fluoro, chloro, bromo, trifluoromethyl, substituted phenyl, cyano, methoxy, nitro, hydroxyl, —C(O)-saccharide and —H; and
Rd is —NH—C 1-6 -alkyl (branched or linear), —O—C 1-6 -alkyl (branched or linear), a saccharide or —OH,
wherein the compound or salt is crystalline.

3. The compound according to claim 1 , wherein said compound is (Z)-6-((2S,4S,5R)-2-(2-chlorophenyl)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl)-hex-4-enoic acid.

4. The compound according to claim 1 , wherein said compound is (Z)-6-((2S,4S,5R)-2-(2-chlorophenyl)-4-(2-methoxyphenyl)-1,3-dioxan-5-yl)-hex-4-enoic acid.

5. The compound according to claim 1 , wherein said compound is (Z)-6-((2S,4S,5R)-2-(2-chlorophenyl)-4-(2-acetoxyphenyl)-1,3-dioxan-5-yl)-hex-4-enoic acid.

6. The compound according to claim 1 , wherein said compound is methyl-(Z)-6-((2S,4S,5R)-2-(2-chlorophenyl)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl)hex-4-enoate.

7. A method of treating a clinical condition associated with activity of the thromboxane receptor, the thromboxane A2 receptor or the prostaglandin H2 receptor in an individual in need thereof, said method comprising a therapeutically effective amount of a compound of formula XI:

or a pharmaceutically acceptable salt thereof
wherein X is selected from the group consisting of fluoro, chloro, bromo, trifluoromethyl, substituted phenyl, cyano, methoxy, nitro, hydroxyl and —H; and
Y is selected from the group consisting of fluoro, chloro, bromo, trifluoromethyl, substituted phenyl, cyano, methoxy, nitro, hydroxyl, —C(O)-saccharide and —H; and
Rd is —NH—C 1-6 -alkyl (branched or linear), —O—C 1-6 -alkyl (branched or linear), a saccharide or —OH.

8. The method according to claim 7 , wherein said clinical condition is selected from the group consisting of myocardial infarction, thrombosis, thrombotic disorders, pulmonary hypertension, atherosclerosis, diabetic nephropathy, retinopathy, peripheral arterial disease, lower limb circulation, pulmonary embolism, thrombus formation, stent-triggered thrombus formation, stent-triggered hyperplasia, stent-induced restenosis, hyperplasia, septic shock, preeclampsia, asthma, rhinitis, allergic rhinitis, tumor angiogenesis and metastasis.

9. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 .

Assignees

• Sorensen Alexandra Santana
• Meyer Jean-Philippe
• Alberts Peteris
• Mainkar Prathama S
• Crameri Melya Hughes
• Evolva Sa

Inventors

• Sorensen Alexandra Santana
• Meyer Jean-Philippe
• Alberts Peteris
• Mainkar Prathama S
• Crameri Melya Hughes

Classifications

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P9/12

  Antihypertensives · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P7/02

  Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title

• A61P3/04

  Anorexiants; Antiobesity agents · CPC title